

CITATION REPORT

List of articles citing

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

DOI: 10.1136/bmj.321.7273.1371

BMJ: British Medical Journal, 2000, 321, 1371-6.

Source: <https://exaly.com/paper-pdf/31994648/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
772	Atypical antipsychotics. <i>BMJ: British Medical Journal</i> , 2000 , 321, 1360-1		31
771	Paclitaxel + liposomal doxorubicin regimen beneficial in metastatic breast cancer. 2000 , &NA;, 17		
770	Amisulpride: a review of its use in the management of schizophrenia. 2001 , 61, 2123-50		52
769	Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. 2001 , 50, 873-83		294
768	Broad therapeutic uses of atypical antipsychotic medications. 2001 , 50, 912-24		60
767	Choosing the right dose of antipsychotics in schizophrenia: lessons from neuroimaging studies. 2001 , 15, 671-8		60
766	Choosing antipsychotic drugs in schizophrenia: A personal view. 2001 , 25, 284-286		3
765	Recent advances in evidence-based psychiatry. <i>Canadian Journal of Psychiatry</i> , 2001 , 46, 403-6	4.8	12
764	Trifluoperazine for schizophrenia. 2001 ,		2
763	Psychiatric services in developing countries. <i>British Journal of Psychiatry</i> , 2001 , 179, 368-9	5.4	
762	Psychotropic drug use in Italy, 1984-99: the impact of a change in reimbursement status. 2001 , 16, 227-33		20
761	Medical Care of Persons With Severe Mental Illness. 2001 , 4, 103-112		
760	["What's up, doc?" The context, limitations, and issues for clinicians in evidence-based medicine]. <i>Canadian Journal of Psychiatry</i> , 2001 , 46, 396-402	4.8	6
759	Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. 2001 , 16, 325-30		36
758	Managing schizophrenia: an update. 2001 , 62, 549-52		
757	Treatment-refractory schizophrenia. 2001 , 3, 393-400		5
756	Atypische antipsychotica bij schizofrenie. 2001 , 39, 260-260		

755	Commentary: The Management of Drug Expenditure Requires a Broad Perspective. 2001 , 9, 252-253		
754	Current Awareness. 2001 , 16, 287-292		
753	Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. <i>BMJ: British Medical Journal</i> , 2001 , 322, 1207-9		151
752	Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine. 2001 , 35, 1517-22		24
751	Understanding antipsychotic drug tolerability. 2001 , 35, 1659-60		1
750	The pharmaceutical industry and mental health nursing. 2001 , 10, 1396-402		9
749	New-onset seizure associated with quetiapine and olanzapine. 2002 , 36, 437-9		35
748	A systematic review of the use of atypical antipsychotics in autism. 2002 , 16, 93-101		98
747	[A systemic review of the European Agency for the evaluation of medicinal products (EMA) recommendations on the conduct of clinical trials in psychiatry]. 2002 , 11, 28-34		1
746	The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia. 2002 , 7, 247-53		46
745	Parkinson's disease and anaesthesia. 2002 , 89, 904-16		118
744	The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. 2002 , 302, 1129-34		135
743	Use of atypical antipsychotics by consultant psychiatrists working in forensic settings. 2002 , 26, 172-174		4
742	Nithsdale Schizophrenia Surveys 23: movement disorders. 20-year review. <i>British Journal of Psychiatry</i> , 2002 , 181, 422-7	5.4	64
741	Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. 2002 , 190, 583-92		100
740	Commentary: how the doctor can counter commercial bias in the dissemination of pharmacotherapeutic knowledge. 2002 , 190, 593-6		1
739	Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia. 2002 , 22, 554-60		24
738	Research on the Drug Treatment of Schizophrenia. 2002 , 38, 217-239		19

737 Antipsychotic drugs. **2002**, 25, 53-77

736 II The usefulness of the second-generation antipsychotic medications. **2002**, 15, S7-S16

4

735 Recent studies on the neurocognitive effects of second-generation antipsychotic medications. **2002**, 15, 25-29

14

734 The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. **2002**, 51, 972-8

170

733 Another view of therapy for cognition in schizophrenia. **2002**, 51, 969-71

95

732 Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. *Schizophrenia Research*, **2002**, 57, 201-8

3.6 90

731 Happy birthday neuroleptics! 50 years later: la folie du doute. **2002**, 17, 115-9

16

730 Use of antipsychotic agents in Spain through 1985-2000. **2002**, 17, 471-6

31

729 Frequency of Extrapyramidal Adverse Reactions in Schizophrenic Outpatients Treated with Risperidone, Olanzapine, Quetiapine or Haloperidol : Results of the EIRE Study. **2002**, 22, 609-622

6

728 Prevention of relapse in schizophrenia. **2002**, 346, 56-8

34

727 Effects of newer antipsychotics on extrapyramidal function. **2002**, 16, 23-45

206

726 Interactions between psychotropics, anaesthetics and electroconvulsive therapy: implications for drug choice and patient management. **2002**, 16, 229-47

52

725 Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. **2002**, 16, 473-84

131

724 Genetics and etiopathophysiology of schizophrenia. **2002**, 77, 1068-82

17

723 ¡Feliz cumpleaños, neurolepticos! Cincuenta años después: la locura de la duda. **2002**, 9, 351-356

722 Mental health policy and evidence. Potentials and pitfalls. **2002**, 26, 324-327

8

721 Rapid tranquillisation: time for a reappraisal of options for parenteral therapy. *British Journal of Psychiatry*, **2002**, 180, 485-9

5.4 72

720 Atypical antipsychotics. **2002**, 26, 36-36

2

719	Regional selectivity of novel antipsychotics. <i>British Journal of Psychiatry</i> , 2002 , 181, 254-5; author reply 255	5.4	1
718	Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. 2002 , 27, 1071-81		79
717	Itemized clinician ratings versus global ratings of symptom severity in patients with schizophrenia. 2002 , 11, 45-53		2
716	Second generation antipsychotics. 2002 , 162, 90-1		9
715	Antipsychotic use in Australia: the patients' perspective. 2002 , 36, 633-41		38
714	Reply to Dziewas and Henningsen. 'Medicine psychiatry and euthenasia: an urgent against mandatory psychotic review'. 2002 , 36, 558		
713	Antipsychotics and the law. 2002 , 36, 560-1		
712	Variations in prescribing atypical antipsychotic drugs in primary care: cross-sectional study. 2002 , 11, 285-9		31
711	NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. 2002 , 7, 837-44		360
710	The history of community mental health treatment and rehabilitation for persons with severe mental illness. 2003 , 39, 427-40		52
709	Pharmacoeconomics: the new dismal science. 2004 , 31, 425-7		
708	Efficacy of second-generation antipsychotics in the treatment of schizophrenia. 2003 , 1, 7-14		
707	Varying and "atypical" indications for atypical antipsychotics. 2003 , 169, 205-6		21
706	Second-generation antipsychotics: discrepancies between licensed indications, evidence base and actual use. 2003 , 169, 207-10		8
705	Clozapine and olanzapine, but not haloperidol, reverse cold-induced and lipopolysaccharide-induced cutaneous vasoconstriction. 2004 , 175, 487-93		8
704	Short-acting parenteral antipsychotics drive choice for classical versus atypical agents. 2003 , 58, 757-60		6
703	Is there evidence that palliative care teams alter end-of-life experiences of patients and their caregivers?. 2003 , 25, 150-68		401
702	The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. 2003 , 18, 432-40		61

701	Schizophrenia: from phenomenology to neurobiology. 2003 , 27, 269-306		202
700	Quetiapine poisoning: a case series. 2003 , 42, 751-8		96
699	The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. 2003 , 107, 222-32		87
698	Evidence-based practices in geriatric mental health care: an overview of systematic reviews and meta-analyses. 2003 , 26, 971-90, x-xi		42
697	Treatment of schizophrenia: preventing the progression of disease. 2003 , 26, 367-79		8
696	Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. 2003 , 63, 493-512		89
695	Acute and maintenance ECT with flupenthixol in refractory schizophrenia: sustained improvements in psychopathology, quality of life, and social outcomes. <i>Schizophrenia Research</i> , 2003 , 63, 189-93	3.6	64
694	Antipsychotic treatment in schizophrenia: atypical options and NICE guidance. 2003 , 18, 209-19		13
693	Schizophrenia: improving the treatment through increased understanding. 2003 , 18 Suppl 2, 25s-26s		
692	Second-generation antipsychotics: are their similarities greater than their differences?. 2003 , 18 Suppl 2, 38s-45s		
691	Half a century of antipsychotics and still a central role for dopamine D2 receptors. 2003 , 27, 1081-90		445
690	New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. 2003 , 361, 1581-9		500
689	New generation versus conventional antipsychotics. 2003 , 362, 404; author reply 404-5		4
688	Effects of quetiapine on gonadal axis hormones in male patients with schizophrenia: a preliminary, open study. 2003 , 27, 875-8		2
687	Evaluating health interventions: exploiting the potential. 2003 , 63, 215-26		24
686	Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. 2003 , 17, 149-73; discussion 147		317
685	Response to the commentaries. 2003 , 12, 363-367		4
684	Treatment of depressive symptoms with quetiapine. 2003 , 3, 417-23		3

683	Management of the negative symptoms of schizophrenia: new treatment options. 2003 , 17, 793-823		95
682	Cost-effectiveness of amisulpride compared with risperidone in patients with schizophrenia. 2003 , 6, 31-41		3
681	Comparison of systematic and narrative reviews: the example of the atypical antipsychotics. 2003 , 12, 146-53		65
680	Clinical trial response and dropout rates with olanzapine versus risperidone. 2003 , 37, 556-63		18
679	Cost-effectiveness of current and optimal treatment for schizophrenia. <i>British Journal of Psychiatry</i> , 2003 , 183, 427-35; discussion 436	5.4	65
678	Novel antipsychotic agents: recent advances in the drug treatment of schizophrenia. 2003 , 13, 425-448		4
677	Atypical and conventional antipsychotic drugs in treatment-naïve first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. 2003 , 28, 995-1003		273
676	Neurocognitive performance and clinical changes in olanzapine-treated patients with schizophrenia. 2003 , 28, 2029-36		16
675	Haematological safety of antipsychotic drugs. 2003 , 2, 395-9		35
674	How can research ethics committees protect patients better?. 2003 , 326, 1199-201		24
673	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. 2003 , 4, 5-13		124
672	Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. 2003 , 28, 1491-500		62
671	The siren call of new drugs. 2003 , 3, 513-5		3
670	Prevalence and correlates of obesity in a community sample of individuals with severe and persistent mental illness. 2003 , 191, 799-805		73
669	From chlorpromazine to clozapine--antipsychotic adverse effects and the clinician's dilemma. <i>Canadian Journal of Psychiatry</i> , 2003 , 48, 749-55	4.8	28
668	Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination. <i>British Journal of Psychiatry</i> , 2003 , 183, 161-6	5.4	60
667	Recommendations. 2003 , 16, S21-S28		
666	Neuropsychology in schizophrenia: an update. 2003 , 16, 149-155		52

665	Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. 2003 , 18, 121-132	7
664	Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. 2003 , 18, 121-32	46
663	Depot risperidone for schizophrenia. 2003 , CD004161	14
662	Positron emission tomography (PET) neurochemistry: where are we now and where are we going?. 2003 , 181-194	
661	Translating advances in schizophrenia treatment: a glass ceiling. 2003 , 178, 425-6	3
660	[Diabetes mellitus and atypical antipsychotics]. 2003 , 25, 253-7	9
659	Postcode prescribing for schizophrenia. <i>British Journal of Psychiatry</i> , 2003 , 182, 281-3	5-4 17
658	The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning. 2004 , 116, 49-51, 55-9, 63	18
657	Risperidone long-acting injection: the first 50 patients. 2004 , 28, 12-14	14
656	Material-specific episodic memory associates of the psychomotor poverty syndrome in schizophrenia. 2004 , 9, 213-27	16
655	Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. 2004 , 29, 1230-8	146
654	Introduction to systematic reviews. 2004 , 18, 249-50	4
653	Review: Newer antipsychotic agents, carbohydrate metabolism and cardiovascular risk. 2004 , 4, 303-309	5
652	Clinical outcome of an early psychosis intervention program: evaluation in a real-world context. 2004 , 38, 694-701	22
651	Differences of satisfaction with medication between patients with schizophrenia treated with typical antipsychotics and atypical antipsychotics. 2004 , 58, 268-73	7
650	Risk:benefit assessment of old medicines. 2004 , 58, 581-6	5
649	Off-label and non-classical prescriptions of antipsychotic agents in ordinary in-patient practice. 2004 , 109, 275-8	35
648	Decrease of antiparkinsonian drugs before start of an antipsychotic in patients on levodopa treatment?. 2004 , 26, 277-81	0

647	Prescription of psychotropic drugs to patients with schizophrenia: an Italian national survey. 2004 , 60, 513-22	42
646	Effect of second-generation antipsychotics on employment and productivity in individuals with schizophrenia: an economic perspective. 2004 , 22, 701-18	27
645	Neuropsychotherapeutics in the UK: what has been the impact of NICE on prescribing?. 2004 , 18, 1-12	19
644	Amisulpride: a review of its use in the management of schizophrenia. 2004 , 18, 933-56	78
643	Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. 2004 , 47, 143-57	53
642	Long-acting risperidone: a review of its use in schizophrenia. 2004 , 18, 113-32	81
641	[Central dopaminergic receptors (Part II): pathophysiological and therapeutic considerations]. 2004 , 160, 986-92	1
640	Less medication switching after initial start with atypical antipsychotics. 2004 , 14, 1-5	6
639	A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. 2004 , 55, 1013-22	243
638	Atypical Antipsychotics as First-Line Treatments for Schizophrenia. 2004 , 12, 169-179	4
637	Adverse effects of risperidone and haloperidol treatment in schizophrenia. 2004 , 28, 285-90	20
636	Comparison of risperidone and olanzapine as used under "real-world" conditions in a state psychiatric hospital. 2004 , 28, 487-95	10
635	Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications. 2004 , 129, 101-7	87
634	[Leponex, 10 years after -- a clinical review]. 2004 , 30, 474-91	12
633	Is it worth while changing clinically stable schizophrenic out-patients with mild to moderate residual symptoms and/or side effects from conventional to atypical antipsychotics? A prospective, randomised study with olanzapine. 2004 , 19, 516-8	15
632	The case against antipsychotic drugs: a 50-year record of doing more harm than good. 2004 , 62, 5-13	64
631	Effective dosing and dose equivalency of second-generation antipsychotic medications. 2004 , 9, 24-31	3
630	Dose response and dose equivalence of antipsychotics. 2004 , 24, 192-208	238

629	Subjective response to antipsychotics of schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. 2004 , 24, 245-54	34
628	Management of early-onset psychosis. 2004 , 17, 249-254	3
627	Trifluoperazine for schizophrenia. 2004 , CD003545	25
626	Clinical rating scales and instruments: how do they compare in assessing abnormal, involuntary movements?. 2004 , 24, 298-304	29
625	Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. 2004 , 24, 582-91	53
624	Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. 2004 , 24, S7-14	97
623	The newer antipsychotics: underlying mechanisms and the new clinical realities. 2004 , 17, 115-121	9
622	Evidence for use of depot neuroleptic medication. 2004 , 21, 95-99	
621	A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. 2004 , 19, 63-9	64
620	Aripiprazole alone or in combination for acute mania. 2004 ,	
619	Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naïve schizophrenic patients. 2004 , 9, 364-74	43
618	Antipsychotic drugs. 2004 , 27, 49-71	
617	From clinical research to clinical practice: a 4-year review of ziprasidone. 2005 , 10, 1-20	22
616	Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. 2005 , 25, 427-34	45
615	Rational pharmacotherapy in early psychosis. <i>British Journal of Psychiatry</i> , 2005 , 48, s77-84	5.4 18
614	Neuropsychiatric sequelae of neuroleptic malignant syndrome. 2005 , 28, 197-204	19
613	Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. 2005 , 28, 163-8	42
612	New Drugs, New Problems. 2005 , 37, 9-25	1

611	Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. 2005 , 20, 183-98	69
610	Modalit� d'utilisation des neuroleptiques. 2005 , 2, 1-27	1
609	Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines for the Treatment of Schizophrenia and Related Disorders. 2005 , 39, 1-30	167
608	Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. 2005 , 39, 1-30	225
607	Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. 2005 , 10, 79-104	737
606	Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. 2005 , 111, 220-31	77
605	[Correlation analysis between antipsychotic prescription quality and clinical status of patients with schizophrenia]. 2005 , 29, 95-103	2
604	Subjective experiences on antipsychotic medications: synthesis and conclusions. 2005 , 111, 43-6	37
603	Validation of the tremulous jaw movement model for assessment of the motor effects of typical and atypical antipsychotics: effects of pimozide (Orap) in rats. 2005 , 80, 351-62	36
602	Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone. 2005 , 20, 573-81	17
601	Predictors and markers of clozapine response. 2005 , 179, 317-35	30
600	Impact of regulatory changes on first- and second-generation antipsychotic drug consumption and expenditure in Italy. 2005 , 40, 72-7	17
599	Metaanalyses - highest level of empirical evidence?. 2005 , 255, 369-70	11
598	First- and second-generation antipsychotic medication and cognitive processing in schizophrenia. 2005 , 7, 304-10	33
597	Patterns of prescription of four major antipsychotics: a retrospective study based on medical records of psychiatric inpatients. 2005 , 14, 805-11	8
596	Do maternal folate and homocysteine levels play a role in neurodevelopmental processes that increase risk for schizophrenia?. 2005 , 13, 197-205	55
595	Evaluation of an antipsychotic information sheet for patients. 2005 , 9, 264-70	3
594	Is there a differential efficacy of new generation antipsychotic drugs?. 2005 , 9, 154-6	

593	Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. 2005 , 30, 1532-8	156
592	Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. 2005 , 19, 110-7	51
591	The impact of European regulatory policies on psychotropic drug prescribing patterns. 2005 , 17, 199-204	5
590	Large simple trials in psychiatry: providing reliable answers to important clinical questions. 2005 , 14, 122-6	25
589	Co-morbidity and Associated Clinical Problems in Schizophrenia: Their Nature and Implications for Comprehensive CognitiveâBehavioural Treatment. 2005 , 22, 125-142	19
588	Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. 2005 , 30, 445-60	104
587	Assessing Cost-Effectiveness of Drug Interventions for Schizophrenia. 2005 , 39, 44-54	23
586	Comparing efficacy of first-line atypical antipsychotics: no evidence of differential efficacy between risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole. 2005 , 9, 204-12	16
585	Assessing cost-effectiveness in mental health: helping policy-makers prioritize and plan health services. 2005 , 39, 701-12	66
584	Establishing a doseâResponse relationship for haloperidol decanoate. 2005 , 29, 104-107	10
583	Old versus new: weighing the evidence between the first- and second-generation antipsychotics. 2005 , 20, 7-14	17
582	Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. 2005 , 20, 15-27	122
581	Modelling the treated course of schizophrenia: development of a discrete event simulation model. 2005 , 23 Suppl 1, 17-33	37
580	Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. 2005 , 23 Suppl 1, 62-74	42
579	Efficacy of olanzapine and ziprasidone for the treatment of schizophrenia: a systematic review. 2005 , 19, 499-515	7
578	Head-to-head comparison of the costs of atypical antipsychotics: a systematic review. 2005 , 19, 935-50	14
577	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. 2005 , 6, 132-91	216
576	Does clozapine work by blocking spikes and sparing bursts?. 2005 , 65, 68-78	3

575	Patterns of clinical use of antipsychotics in hospitalized psychiatric patients. 2005 , 29, 957-63		11
574	Lack of extrapyramidal side effects predicts quality of life in outpatients treated with clozapine or with typical antipsychotics. 2005 , 133, 277-80		30
573	Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. 2005 , 353, 1209-23		4423
572	Extrapyramidal symptoms with atypical antipsychotics : incidence, prevention and management. 2005 , 28, 191-208		135
571	Modalit�� d'utilisation des neuroleptiques. 2005 , 2, 300-339		4
570	The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. <i>Schizophrenia Research</i> , 2005 , 78, 147-56	3.6	77
569	Modern antipsychotic drugs: a critical overview. 2005 , 172, 1703-11		261
568	Old versus new medications: how much should be taught?. 2005 , 29, 162-6		12
567	Atypical antipsychotic drugs, diabetes and ethnicity. 2005 , 4, 1111-24		15
566	Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. 2006 , 20, 389-409		315
565	The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. 2006 , 20, 293-301		64
564	Adverse drug reactions of antidepressants and antipsychotics: experience, knowledge and attitudes among Norwegian psychiatrists. 2006 , 60, 227-33		6
563	[Cognition, schizophrenia and the effect of antipsychotics]. 2006 , 32, 341-50		46
562	Optimisation of long-term treatment in schizophrenia: treating the true spectrum of symptoms. 2006 , 16 Suppl 3, S135-41		17
561	Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. 2006 , 21, 11-20		48
560	Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. 2006 , 333, 224		260
559	A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). <i>Schizophrenia Research</i> , 2006 , 84, 77-89	3.6	77
558	Olanzapine and haloperidol in first episode psychosis: two-year data. <i>Schizophrenia Research</i> , 2006 , 86, 234-43	3.6	102

557	Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. <i>Schizophrenia Research</i> , 2006 , 88, 5-25	3.6	156
556	Decision making about children with psychotic symptoms: using the best evidence in choosing a treatment. 2006 , 45, 1381-6		8
555	Impact of second-generation antipsychotics on the use of antiparkinson agents in nursing homes and assisted-living facilities. 2006 , 4, 25-35		7
554	Long-acting risperidone: focus on safety. 2006 , 28, 633-51		20
553	Haloperidol and atypical antipsychotics share a same action of decreasing P75(NTR) mRNA levels in PC12 cells. 2006 , 79, 570-4		7
552	Assessing side effects of pharmacotherapy treatment of bipolar disorder: a 20-year review of the literature. 2006 , 27, 467-500		17
551	Antipsychotic-associated neuronal changes in the brain: toxic, therapeutic, or irrelevant to the long-term outcome of schizophrenia?. 2006 , 30, 174-89		38
550	Schizophrenia and schizophrenia-like disorders. 79-109		
549	Behavior Analysis of Psychotic Disorders: Scientific Dead End or Casualty of the Mental Health Political Economy?. 2006 , 15, 152-177		20
548	Interpreting the efficacy findings in the CATIE study: what clinicians should know. 2006 , 11, 14-24		37
547	A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. 2006 , 21, 49-56		41
546	Chapter 6 Pharmacological treatment. 2006 , 109-141		
545	Haloperidol alone or in combination for acute mania. 2006 , CD004362		28
544	ECT for treatment-resistant schizophrenia: a response from the far East to the UK. NICE report. 2006 , 22, 4-12		34
543	A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia. 2006 , 26, 238-49		42
542	Translating research into clinical practice: critical interpretation of clinical trials in schizophrenia. 2006 , 21 Suppl 2, S1-10		5
541	Implications of the CATIE trial on treatment: extrapyramidal symptoms. 2006 , 11, 25-31		50
540	Understanding the results of CATIE in the context of the field. 2006 , 11, 40-7		11

539	[PET (positron emission tomography) research on schizophrenia]. 2006 , 128, 177-83	
538	Prevalence, incidence and persistence of antipsychotic drug prescribing in the Italian general population: retrospective database analysis, 1999-2002. 2006 , 15, 412-20	23
537	Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophrenia. 2006 , 60, 751-7	4
536	Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy. 2006 , 113, 135-41	41
535	Data mining in spontaneous reports. 2006 , 98, 324-30	25
534	Treatment of psychosis: 30 years of progress. 2006 , 31, 523-34	38
533	Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. 2006 , 5, 133-46	39
532	Campus mental health services: recommendations for change. 2006 , 76, 226-237	213
531	Antipsychotics in early onset Schizophrenia: Systematic review and meta-analysis. 2006 , 15, 141-8	46
530	Pharmacokinetic and behavioral characterization of a long-term antipsychotic delivery system in rodents and rabbits. 2007 , 190, 201-11	16
529	Pharmacologic treatment of schizophrenia: Current status and future trends. 2006 , 4, 40-49	1
528	Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons. 2006 , 6, 30	15
527	Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. 2006 , 6, 8	82
526	[Positive and negative aspects of pharmaceutical services in Spain: about antidepressants and antipsychotics]. 2006 , 20 Suppl 1, 143-53	6
525	Pharmacotherapy of delusional disorders in the context of offending and the potential for compulsory treatment. 2006 , 24, 351-67	14
524	A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration. 2006 , 21, 171-9	23
523	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. 2006 , 7, 5-40	118
522	Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. <i>British Journal of Psychiatry</i> , 2006 , 189, 433-40	5.4 68

521	Medication-free research in early episode schizophrenia: evidence of long-term harm?. 2006 , 32, 288-96	31
520	Psychosocial Acute Treatment in Early-Episode Schizophrenia Disorders. 2006 , 16, 263-275	1
519	Meta-analysis in the assessment of treatment outcome. 2006 , 20, 67-71	7
518	Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses. 2006 , 20, 20-37	50
517	Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. 2006 , 164, 672-81	88
516	The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review. 2006 , 20, 335-46	45
515	Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. 2007 , 33, 183-91	156
514	[Pharmacoeconomic evaluations on antipsychotics in schizophrenia: a review of the Italian studies]. 2006 , 15, 153-60	
513	Symptom domains of schizophrenia: the role of atypical antipsychotic agents. 2006 , 20, 6-19	37
512	Effectiveness and tolerability of schizophrenia treatment in Central and Eastern Europe: results after 1 year from a prospective, observational study (IC-SOHO). 2006 , 10, 78-90	2
511	Current schizophrenia drugs: efficacy and side effects. 2006 , 7, 1005-16	33
510	âReal worldâ study of antipsychotic effectiveness for chronic inpatients with schizophrenia in a state psychiatric hospital: Preliminary results and commentary. 2006 , 15, 57-62	2
509	A review of atypical antipsychotic drugs versus conventional medication in schizophrenia. 2006 , 7, 1739-48	34
508	Rationale for emphasis on management over treatment of schizophrenia in clinical practice. 2007 , 41, 693-5	3
507	Randomized controlled trials for schizophrenia: study designs targeted to distinct goals. 2008 , 34, 266-74	11
506	Has research informed us on the practical drug treatment of schizophrenia?. 2008 , 34, 403-5	2
505	Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial. 2007 , 7, 103-11	20
504	On the relationship of atypical and low-dose conventional antipsychotics with akathisia in a clinical patient population. 2007 , 61, 152-7	5

- 503 Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders. **2007**, 13, 230-43 33
- 502 Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics. *British Journal of Psychiatry*, **2007**, 191, 238-45 5.4 27
- 501 Adverse effects of antipsychotics as outcome measures. *British Journal of Psychiatry*, **2007**, 50, s64-70 5.4 39
- 500 PET and SPECT imaging in psychiatric disorders. *Canadian Journal of Psychiatry*, **2007**, 52, 146-57 4.8 62
- 499 Prescribing medication in first episode psychosis. **2007**, 5, 335-343
- 498 [Programs for first onset psychosis and evidence-based medicine: a case of the syndrome of the emperor's new clothes]. **2007**, 32, 333-49 2
- 497 Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. *British Journal of Psychiatry*, **2007**, 191, 14-22 5.4 82
- 496 Neuroleptic malignant syndrome from aripiprazole in an agitated pediatric patient. **2007**, 30, 47-51 16
- 495 Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. **2007**, 22, 145-52 23
- 494 Tardive dyskinesia: eliminated, forgotten, or overshadowed?. **2007**, 20, 131-7 52
- 493 Measuring movement disorders in antipsychotic drug trials: the need to define a new standard. **2007**, 27, 423-30 30
- 492 Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride. **2007**, 22, 175-8 6
- 491 Chapter 5.. **2007**, 21, 97-123 1
- 490 Determining treatment outcome in early intervention programs for autism spectrum disorders: a critical analysis of measurement issues in learning based interventions. **2007**, 28, 207-18 132
- 489 Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms. **2007**, 31, 1012-22 20
- 488 Adverse childhood experiences and prescribed psychotropic medications in adults. **2007**, 32, 389-94 219
- 487 Antipsicóticos típicos. Antipsicóticos atípicos. **2007**, 14, 637-647
- 486 Respuesta de los autores. **2007**, 128, 36-37

485	[Antipsychotic agents: what do meta analyses say?]. 2007 , 33 Pt 3, S419-24			
484	Le traitement des formes déficitaires de schizophrénie. 2007 , 33, 11-15			0
483	Discussion. 2007 , 33, 56-57			1
482	Bénéfices comparés des anti-psychotiques atypiques versus neuroleptiques classiques. 2007 , 33, 150-152			0
481	Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities. 2007 , 50, 865-76			35
480	A systematic review of the Soteria paradigm for the treatment of people diagnosed with schizophrenia. 2008 , 34, 181-92			63
479	Dopamine and serotonin receptor binding and antipsychotic efficacy. 2007 , 32, 1715-26			98
478	Treatment-resistant schizophrenia. 2007 , 30, 511-33			129
477	A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. <i>Schizophrenia Research</i> , 2007 , 89, 211-24	3.6	111	
476	Schizophrenia: new pathological insights and therapies. 2007 , 58, 49-61			95
475	Adverse effects of atypical antipsychotics : differential risk and clinical implications. 2007 , 21, 911-36			286
474	Schizophrenia. 2007 ,			
473	Pharmacotherapy of Schizophrenia. 2007 ,			1
472	[Refractory schizophrenia]. 2007 , 29 Suppl 2, S41-7			27
471	Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine. 2007 , 29, 207-12			26
470	Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study. 2007 , 81, 586-94			38
469	Managing Psychotic Illness in Young People: A Practical Overview. 2007 , 12, 173-186			3
468	The case for long-acting antipsychotic agents in the post-CATIE era. 2007 , 115, 260-7			117

467	Social functioning as an outcome measure in schizophrenia studies. 2007 , 116, 403-18	207
466	PDE inhibitors in psychiatry--future options for dementia, depression and schizophrenia?. 2007 , 12, 870-8	80
465	How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. 2007 , 195, 285-95	43
464	Pharmacotherapy for schizophrenia and co-occurring substance use disorders. 2007 , 11, 33-40	20
463	[Meta-analyses. A tool for maximizing therapy study evidence?]. 2007 , 78, 1028-36	8
462	Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics-a European study. 2007 , 29, 126-30	56
461	Do we learn the right things from clinical trials?. 2008 , 64, 115-25	2
460	Incorporating clinical guidelines through clinician decision-making. 2008 , 3, 13	2
459	Neurological complications of psychiatric drugs: clinical features and management. 2008 , 23 Suppl 1, 15-26	129
458	History, context, process, and rationale for the development of clinical guidelines. 2008 , 81, 331-50	18
457	Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. 2008 , 13, 918-29	82
456	A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine. 2008 , 11, 549-62	25
455	The cost-effectiveness of atypicals in the UK. 2008 , 11, 1007-21	17
454	Creating a space for recovery-focused psychiatric nursing care. 2008 , 15, 251-9	20
453	The self-efficacy model of medication adherence in chronic mental illness. 2008 , 17, 329-40	17
452	Beta-blocker and angiotensin-converting enzyme inhibitor may limit certain cardiac adverse effects of clozapine. 2008 , 30, 280-3	18
451	New and old antipsychotics: what "Effectiveness" trials tell us. 2008 , 7, 443-446	1
450	Late-onset schizophrenia and very late-onset schizophrenia-like psychosis. 2008 , 7, 463-466	2

449	A randomized controlled trial of cognitive-behavior therapy for persistent symptoms in schizophrenia: a five-year follow-up. <i>Schizophrenia Research</i> , 2008 , 98, 1-7	3.6	80
448	Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment. <i>Schizophrenia Research</i> , 2008 , 100, 97-107	3.6	26
447	Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population. <i>Schizophrenia Research</i> , 2008 , 99, 13-22	3.6	89
446	World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. <i>Schizophrenia Research</i> , 2008 , 100, 20-38	3.6	202
445	Diabetic control and atypical antipsychotics: a case report. 2008 , 2, 155		4
444	Antipsychotic-induced extrapyramidal symptoms and their management. 2008 , 9, 1451-62		62
443	Partial compliance in schizophrenia and the impact on patient outcomes. 2008 , 161, 235-47		123
442	Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. 2008 , 32, 405-13		43
441	Antipsychotic prescriptions in a university hospital outpatient population in Turkey: a retrospective database analysis, 2005-2006. 2008 , 32, 968-74		2
440	Limitations of current therapies: why do patients switch therapies?. 2008 , 18 Suppl 3, S135-9		7
439	Do we need another atypical antipsychotic?. 2008 , 18 Suppl 3, S146-52		7
438	Antipsychotic drugs for aggression in intellectual disability. 2008 , 371, 9-10		85
437	Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. 2008 , 371, 1085-97		823
436	Psychoeducation for patients with schizophrenia and their families. 2008 , 8, 1067-77		30
435	A pharmacoeconomic analysis of compliance gains on antipsychotic medications. 2008 , 6, 189-97		11
434	Modelling approaches: the case of schizophrenia. 2008 , 26, 633-48		36
433	Classifying antipsychotic agents : need for new terminology. 2008 , 22, 1047-59		12
432	Emerging drugs for schizophrenia. 2008 , 13, 479-95		38

431	A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. 2008 , 22, 238-43		91
430	Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics. 2008 , 9, 1285-306		43
429	Nature of the yeast. 2008 , 1, 770-770		
428	First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. <i>British Journal of Psychiatry</i> , 2008 , 192, 406-11	5.4	196
427	Issues that may determine the outcome of antipsychotic trials: industry sponsorship and extrapyramidal side effect. 2008 , 33, 971-5		20
426	The evolution of drug development in schizophrenia: past issues and future opportunities. 2008 , 33, 2061-79		157
425	Overview of the findings from the European SOHO study. 2008 , 8, 873-80		17
424	Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise. 2008 , 24, 349-58		13
423	Extrapyramidal side-effects of antipsychotics in a randomised trial. <i>British Journal of Psychiatry</i> , 2008 , 193, 279-88	5.4	200
422	What CATIE found: results from the schizophrenia trial. 2008 , 59, 500-6		89
421	CATIE and CUTLASS: can we handle the truth?. <i>British Journal of Psychiatry</i> , 2008 , 192, 161-3	5.4	108
420	Treatment of psychoses in children and adolescents. 819-829		
419	Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia. 2008 , 28, 69-73		32
418	Predictors for starting depot administration of risperidone in chronic users of antipsychotics. 2008 , 28, 625-30		8
417	Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. 2008 , 28, S29-35		139
416	The effectiveness of guideline implementation strategies on improving antipsychotic medication management for schizophrenia. 2008 , 46, 686-91		22
415	Are second generation antipsychotics a distinct class?. 2008 , 14, 225-31		5
414	Pharmacological treatments for schizophrenia. 459-468		

413	Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. 2008 , 2, 67-77		39
412	How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia. 2008 , 14, 17-28		14
411	Differential diagnoses and management strategies in patients with schizophrenia and bipolar disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2008 , 4, 311-7	3.1	24
410	Off-target effects of psychoactive drugs revealed by genome-wide assays in yeast. 2008 , 4, e1000151		71
409	Review of the efficacy of placebo in comparative clinical trials between typical and atypical antipsychotics. 2009 , 31, 52-6		8
408	Update on the management of symptoms in schizophrenia: focus on amisulpride. <i>Neuropsychiatric Disease and Treatment</i> , 2009 , 5, 267-77	3.1	15
407	Effectiveness as an outcome measure for treatment trials in psychiatry. <i>World Psychiatry</i> , 2009 , 8, 23-7	14.4	14
406	Extrapyramidal symptoms and medication use in Mucopolysaccharidosis type III. 2009 , 34, 275-9		9
405	Clinical trial design: horses for courses. <i>World Psychiatry</i> , 2009 , 8, 28-9	14.4	4
404	Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology. 2009 , 23, 346-88		386
403	Second-generation antipsychotics: a therapeutic downturn?. 2009 , 39, 1603-6		3
402	Chlorpromazine dose for people with schizophrenia. 2009 , CD007778		27
401	Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. 2009 , 10, 1917-28		59
400	Packages of care for schizophrenia in low- and middle-income countries. 2009 , 6, e1000165		55
399	Current perspectives in the treatment of resistant schizophrenia. 2009 , 51, 254-60		26
398	Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. 2009 , 35, 931-6		28
397	Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features. 2009 , 35, 775-88		49
396	Quelle est la place de la stimulation magnétique transcrânienne dans la prise en charge des hallucinations de l'enfant souffrant de schizophrénie à début très précoce?. 2009 , 57, 38-43		

395	Noun-verb ambiguity in chronic undifferentiated schizophrenia. 2009 , 42, 74-88	4
394	A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss. 2009 , 9, 32	22
393	Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. 2009 , 206, 491-9	54
392	Outcome study of first-episode schizophrenia in a developing country: quality of life and antipsychotics. 2009 , 44, 143-50	9
391	Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents. 2009 , 65, 1229-35	4
390	How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. 2009 , 14, 429-47	347
389	Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia. 2009 , 86, 84-91	49
388	Psychiatry, mental health nurses, and invisible power: Exploring a perturbed relationship within contemporary mental health care. 2009 , 18, 116-25	56
387	Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study. 2009 , 12, 536-43	47
386	Second-generation antipsychotics for schizophrenia: can we resolve the conflict?. 2009 , 39, 1591-602	132
385	Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior. 2009 , 52, 151-69	71
384	Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. 2009 , 23, 65-73	326
383	Effects of risperidone on cognitive-motor performance and motor movements in chronically medicated children. 2009 , 30, 386-96	23
382	Ethics in clinical research. 2009 , 51, 792-7	20
381	The CATIE and CUTLASS studies in schizophrenia: results and implications for clinicians. 2009 , 23, 649-59	75
380	The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. 2009 , 10, 85-116	251
379	Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials. 2009 , 7, 109-19	13
378	The applicability and generalizability of findings from clinical trials for health-policy decisions. 2009 , 27, 5-10	10

377	Management of patients presenting with acute psychotic episodes of schizophrenia. 2009 , 23, 193-212	30
376	The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study. 2009 , 23, 615-25	72
375	Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. 2009 , 373, 31-41	1385
374	The spurious advance of antipsychotic drug therapy. 2009 , 373, 4-5	80
373	Akathisia and second-generation antipsychotic drugs. 2009 , 22, 293-99	62
372	First- and Second-Generation Antipsychotics and the Concept of "Atypicality" 2009 , 44, 81-88	3
371	Quetiapine versus typical antipsychotic medications for schizophrenia. 2009 ,	2
370	Levomepromazine for schizophrenia. 2009 ,	
369	Antipsychotic drugs. 2009 , 31, 65-104	
368	Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol. 2009 , 14, 93-102	12
367	Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making. <i>Canadian Journal of Psychiatry</i> , 2010 , 55, 117-25	4.8 37
366	An open-label tolerability study of BL-1020 antipsychotic: a novel gamma aminobutyric acid ester of perphenazine. 2010 , 33, 297-302	5
365	Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. 2010 , 53, 4803-7	22
364	Meta-analyses: a method to maximise the evidence from clinical studies?. 2010 , 260, 17-23	16
363	Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations. 2010 , 260, 25-39	31
362	Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment. 2010 , 44, 487-92	21
361	Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety. 2010 , 25, 37-46	12
360	Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome. 2010 , 25, 243-52	27

359	Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. 2010 , 121, 4-10		185
358	Schizophrenia patients discharged against medical advice at a mental hospital in Taiwan. 2010 , 64, 415-20		6
357	Conclusion and implications for practice and policy. 288-306		
356	Schizophrenia and related disorders. 2010 , 391-426		1
355	Effectiveness and efficacy: staying on treatment and symptom reduction. 39-56		
354	Modulation of Central Nitric Oxide as a Therapeutic Strategy for Schizophrenia. 2010 , 20, 115-119		5
353	Safety and tolerability of antipsychotics: focus on amisulpride. 2010 , 2, 205-11		22
352	Un siècle de schizophrénie. 2010 , 86, 391		1
351	Past and present progress in the pharmacologic treatment of schizophrenia. 2010 , 71, 1115-24		161
350	First- and second-generation antipsychotics. <i>Canadian Journal of Psychiatry</i> , 2010 , 55, 144-8; discussion 148-9	4.8	3
349	Extrapyramidal side effects. 156-172		1
348	Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia. 2010 , 24, 1031-5		27
347	Forensic Risk Assessment: A Metareview. 2010 , 37, 965-988		125
346	Sertindole for the treatment of schizophrenia. 2010 , 11, 3053-64		8
345	Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. <i>British Journal of Psychiatry</i> , 2010 , 196, 434-9	5.4	102
344	Antipsychotic dosing and drug delivery. 2010 , 4, 141-77		5
343	Meta-analysis of rates of drop-out from psychosocial treatment among persons with schizophrenia spectrum disorder. <i>Schizophrenia Research</i> , 2010 , 121, 266-70	3.6	60
342	Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. <i>Schizophrenia Research</i> , 2010 , 122, 1-23	3.6	255

341	Progress in defining optimal treatment outcome in schizophrenia. 2010 , 24, 9-20	51
340	Do measures of schizotypal personality provide non-clinical analogues of schizophrenic symptomatology?. 2010 , 176, 150-4	46
339	A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia. 2010 , 177, 286-93	22
338	The association of well-being, productivity and resource use among community-dwelling patients with schizophrenia using atypical antipsychotics. 2010 , 1, 181-187	1
337	Levomepromazine for schizophrenia. 2010 , CD007779	11
336	Applicabilit�e generalizzabilit� dei risultati dei trials clinici nelle decisioni di politica sanitaria. 2010 , 12, 117-122	
335	Cost effectiveness of long-acting risperidone in Sweden. 2010 , 8, 327-41	17
334	Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. 2011 , 29, 127-48, viii	102
333	The rise and fall of the atypical antipsychotics. <i>British Journal of Psychiatry</i> , 2011 , 199, 266-8	5.4 36
332	Practicing evidence-based psychiatry- 2. Interpreting integrative literature: Systematic reviews and meta-analyses. 2011 , 4, 80-5	4
331	Evidence-based pharmacotherapy of schizophrenia. 2011 , 14, 269-84	72
330	Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?. 2011 , 50, 415-28	15
329	The GiSAS study: rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia. 2011 , 32, 675-84	2
328	Psychopharmacology: a house divided. 2011 , 35, 1-10	6
327	A pilot study of antipsychotic prescribing decisions for acutely-ill hospitalized patients. 2011 , 35, 246-51	3
326	Effects of haloperidol on cognition in schizophrenia patients depend on baseline performance: a saccadic eye movement study. 2011 , 35, 1753-64	15
325	Pharmacology and Neuroscience of Antipsychotic Drugs. 2011 , 483-514	
324	Teaching, learning and assessing evidence-based psychiatry. 2011 , 35, 192-195	1

323	The effects of dose of flupentixol decanoate on relapse rates in schizophrenia. 2011 , 35, 293-296		4
322	Clinical potential of lurasidone in the management of schizophrenia. 2011 , 7, 239-50		26
321	Sertindole in the management of schizophrenia. 2011 , 3, 75-85		4
320	Is it Possible to Define a Best Practice Standard for Coercive Treatment in Psychiatry?. 2011 , 49-56		5
319	Pharmacotherapy for treatment-resistant schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2011 , 7, 135-49	3.1	42
318	Clinical utility of the risperidone formulations in the management of schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2011 , 7, 611-20	3.1	11
317	Numbers-needed-to-treat analysis: an explanation using antipsychotic trials in schizophrenia. 2011 , 17, 63-71		6
316	History of Antipsychotic Drug Development. 2011 , 1		
315	Secondary pseudomyopia induced by amisulpride. 2011 , 88, 1380-2		8
314	The impact of antipsychotic side effects on attitudes towards medication in people with schizophrenia and related disorders. 2011 , 20, 2172-82		7
313	Dose-response relationship of sertindole and haloperidol using the pharmacopsychometric triangle. 2011 , 123, 154-61		4
312	Aripiprazole versus haloperidol treatment in early-stage schizophrenia. 2011 , 45, 756-62		12
311	Combination of escitalopram and a 5-HT(α) receptor antagonist selectively decreases the extracellular levels of dopamine in the nucleus accumbens relative to striatum through 5-HT(α) receptor stimulation; suggestive of antipsychotic potential. 2011 , 97, 479-85		11
310	Adjunct mirtazapine for negative symptoms of schizophrenia. 2011 , 31, 1017-30		11
309	Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders. 2011 , 31, 806-12		12
308	Synthesis and biological investigation of potential atypical antipsychotics with a tropane core. Part 1. 2011 , 46, 4474-88		10
307	Effectiveness and costs of flupentixol compared to other first- and second-generation antipsychotics in the treatment of schizophrenia. 2011 , 216, 579-87		5
306	Clozapine associated cardiomyopathy: a cluster of 3 cases. 2011 , 6, 281-3		8

305	Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment. 2011 , 11, 589-607	27
304	Usefulness of NT-pro-BNP and echocardiography in the diagnosis of subclinical clozapine-related cardiotoxicity. 2011 , 31, 712-6	12
303	Powerful choices: peer support and individualized medication self-determination. 2011 , 37, 445-50	12
302	Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review. 2011 , 4, 163-79	3
301	Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option?. 2011 , 11, 989-1006	4
300	Clinical and analytical features of severe suicidal quetiapine overdoses--a retrospective cohort study. 2011 , 49, 846-53	31
299	Development and validation of amisulpride in human plasma by HPLC coupled with tandem mass spectrometry and its application to a pharmacokinetic study. 2011 , 79, 583-99	11
298	Examining the effectiveness of antipsychotic medication in first-episode psychosis. 2012 , 26, 27-32	16
297	Iloperidone-induced Galactorrhea in a Middle-aged Female. 2012 , 34, 396-8	3
296	Full circle-old drugs prove more beneficial than newer agents for schizophrenia: a case report. 2012 , 33, 797-800	
295	Ethical issues raised in addressing the needs of people with serious mental disorders in complex emergencies. 2012 , 6, 72-8	4
294	Use of quetiapine XR and quetiapine IR in clinical practice for hospitalized patients with schizophrenia: a retrospective study. 2012 , 2, 217-26	7
293	The cost-effectiveness of paliperidone extended release in Spain. 2012 , 15 Suppl 1, 26-34	12
292	Payer types associated with antipsychotic polypharmacy in an ambulatory care setting. 2012 , 3, 149-155	4
291	Beyond dopamine: glutamate as a target for future antipsychotics. 2012 , 2012, 427267	22
290	Where Does Evidence from New Trials for Schizophrenia Fit with the Existing Evidence: A Case of the Emperor's New Clothes?. 2012 , 2012, 625738	1
289	Delivery systems and dosing for antipsychotics. 2012 , 267-98	4
288	Antipsychotic medicines in Australian community practice: Effectiveness, adverse effects and quality of life for people with schizophrenia. 2012 , 4, 48-58	

287	One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naïve patients with a first-episode psychosis. 2012 , 200, 693-701	26
286	Pharmacological treatment of schizophrenia. 2012 , 24, 489-98	7
285	A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. 2012 , 13, 1545-73	47
284	Are there different neural mechanisms responsible for three stages of weight gain development in anti-psychotic therapy: temporally based hypothesis. 2012 , 5, 315-8	22
283	Clozapine for the treatment of schizophrenia. 2012 , 13, 1923-35	52
282	Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database. 2012 , 12, 25	11
281	Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug response. 2012 , 7, e49732	27
280	Evidence-based pharmacotherapy of bipolar disorder. 39-52	
279	Evidence-based pharmacotherapy of schizophrenia. 18-38	1
278	Schizophrenia Outpatient Health Outcomes study: twelve-month findings. 2012 , 3, 27-40	4
277	The fall of the atypicals?. <i>British Journal of Psychiatry</i> , 2012 , 200, 256-7; author reply 257	5-4
276	Challenges in validating quality of care data in a schizophrenia registry: experience from the Danish National Indicator Project. 2012 , 4, 201-7	7
275	National changes in oral antipsychotic treatment for people with schizophrenia in primary care between 1998 and 2007 in the United Kingdom. 2012 , 21, 161-9	23
274	A Quantitative Systems Pharmacology Computer Model for Schizophrenia Efficacy and Extrapyramidal Side Effects. 2012 , 73, 196-213	18
273	Influence of the drug exposure definition on the assessment of the antipsychotic metabolic impact in patients initially treated with mood-stabilizers. 2012 , 74, 189-96	7
272	Behavioral screening for neuroactive drugs in zebrafish. 2012 , 72, 373-85	91
271	Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development. 2013 , 40, 257-65	36
270	Atypical antipsychotics and diabetic ketoacidosis: a review. 2013 , 226, 1-12	42

269	Quetiapine versus typical antipsychotic medications for schizophrenia. 2013 , CD007815	16
268	Prevalence of remission and recovery in schizophrenia in the Czech Republic. 2013 , 54, 1111-6	8
267	The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review. 2013 , 31, 1131-54	16
266	Patterns and predictors of antipsychotic medication use among the U.S. population: findings from the Medical Expenditure Panel Survey. 2013 , 9, 263-75	15
265	Why negative meta-analyses may be false?. 2013 , 23, 1307-9	6
264	Atypical antipsychotics in the treatment of depressive and psychotic symptoms in patients with chronic schizophrenia: a naturalistic study. 2013 , 2013, 423205	5
263	Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. 2013 , 23, 118-25	15
262	Antipsychotic medications, glutamate, and cell death: a hidden, but common medication side effect?. 2013 , 80, 252-8	7
261	Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. 2013 , 382, 951-62	1665
260	Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics. 2013 , 56, 4671-90	93
259	Aripiprazole alone or in combination for acute mania. 2013 , CD005000	21
258	Update on typical and atypical antipsychotic drugs. 2013 , 64, 393-406	271
257	Drug treatments for schizophrenia: pragmatism in trial design shows lack of progress in drug design. 2013 , 22, 223-33	9
256	Effectiveness of paliperidone extended-release for patients with schizophrenia: focus on subjective improvement. 2013 , 28, 107-16	11
255	Empowering Alliances in Pursuit of Social Justice: Social Workers Supporting Psychiatric-Survivor Movements. 2013 , 24, 265-288	10
254	Audit of combination and high-dose antipsychotic treatment in the community. 2013 , 37, 302-307	3
253	Use of clozapine in older Asian patients with schizophrenia between 2001 and 2009. 2013 , 8, e66154	15
252	Antipsychotics in the treatment of psychosis: risks and benefits. 2013 , 2, 52-57	

251	Prescribing for personality disorder: qualitative study of interviews with general and forensic consultant psychiatrists. 2014 , 38, 116-21	6
250	Current and future treatment modalities in schizophrenia: novel antipsychotic drugs and cognitive therapy. 2014 , 14, 67-73	4
249	A dopamine D2 receptor-DISC1 protein complex may contribute to antipsychotic-like effects. 2014 , 84, 1302-16	71
248	Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. 2014 , 19, 374-81	31
247	Effect of different antipsychotic drugs on short-term mortality in stroke patients. 2014 , 93, e170	7
246	Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis. 2014 , 44, 37-50	32
245	Pomaglumedad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison. 2014 , 2014, 758212	45
244	Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited. 2014 , 8, 84-90, 90A	1
243	Synthesis and evaluation of new coumarin derivatives as potential atypical antipsychotics. 2014 , 74, 427-39	25
242	Atypical antipsychotic-induced metabolic disturbances in the elderly. 2014 , 31, 159-84	11
241	Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data. 2014 , 15, 133-42	9
240	Antipsychotic treatment of schizophrenia: an update. 2014 , 11, 3-7	47
239	PCP-induced deficits in murine nest building activity: employment of an ethological rodent behavior to mimic negative-like symptoms of schizophrenia. 2014 , 273, 63-72	37
238	Psychopharmacology of the negative symptoms: current status and prospects for progress. 2014 , 24, 788-99	44
237	Depression and impulsivity as pathways to violence: implications for antiaggressive treatment. 2014 , 40, 886-94	32
236	Chronic haloperidol increases voltage-gated Na ⁺ currents in mouse cortical neurons. 2014 , 450, 55-60	5
235	Antipsychotic Drugs. 2015 , 2088-2128	
234	Atypical antipsychotics and movement disorders. 81-90	

233	Quo Vadis Clozapine? A Bibliometric Study of 45 Years of Research in International Context. 2015 , 16, 23012-34	13
232	Comparative efficacy and tolerability of three treatments in old people with osteoporotic vertebral compression fracture: a network meta-analysis and systematic review. 2015 , 10, e0123153	49
231	[Negative symptoms in schizophrenia: new pharmacological approaches]. 2015 , 41, 6S41-9	
230	Tardive dyskinesia (syndrome): Current concept and modern approaches to its management. 2015 , 69, 321-34	52
229	Synthesis and evaluation of amide, sulfonamide and urea α -benzisoxazole derivatives as potential atypical antipsychotics. 2015 , 6, 831-838	12
228	The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. 2015 , 41, 549-58	38
227	Meta-Analysis of Clinical Trials in Bipolar Disorder. 2015 , 13-22	
226	Synthesis and pharmacological evaluation of piperidine (piperazine)-substituted benzoxazole derivatives as multi-target antipsychotics. 2015 , 25, 5299-305	18
225	Role of serotonin 5-HT _{2C} and histamine H ₁ receptors in antipsychotic-induced diabetes: A pharmacoepidemiological-pharmacodynamic study in VigiBase. 2015 , 25, 1556-65	44
224	Comparing antipsychotic treatments for schizophrenia: a health state approach. 2015 , 86, 107-21	1
223	Omega α -fatty acids in schizophrenia α -part I: importance in the pathophysiology of schizophrenia. 2016 , 17, 198-213	1
222	Dose-response meta-analysis of differences in means. 2016 , 16, 91	48
221	Therapeutic Perspective on Tardive Syndrome with Special Reference to Deep Brain Stimulation. 2016 , 7, 207	9
220	Experimental treatment of antipsychotic-induced movement disorders. 2016 , 8, 1-10	13
219	Reasoning and Rehabilitation cognitive skills programme for mentally disordered offenders: Predictors of outcome. 2016 , 6, 410-418	6
218	Studying medication adherence in patients with schizophrenia. <i>Middle East Current Psychiatry</i> , 2016 , 23, 27-34	2.4 3
217	Drug-Induced Extrapyramidal Syndromes: Implications for Contemporary Practice. 2016 , 39, 391-411	45
216	Multi-scale Modeling of Drug Action in the Nervous System. 2016 , 305-324	

215	Treatment-Resistant Schizophrenia. 2016 , 39, 239-65	79
214	Possible biomarkers modulating haloperidol efficacy and/or tolerability. 2016 , 17, 507-29	
213	Prevalence of neuroleptic-induced movement disorders: an 8-year follow-up study in chronic schizophrenia inpatients. 2016 , 70, 498-502	13
212	Clinical Psychopharmacology. 2016 , 707-780	1
211	Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014. 2016 , 6, e011666	76
210	Neuroleptic drugs. 2016 , 53-119	
209	The Oblivion Express: Big Pharma. 2016 , 81-106	
208	Short term effectiveness of haloperidol versus risperidone in first-episode schizophrenia. 2016 , 25, 72-79	1
207	Risperidone (depot) for schizophrenia. 2016 , 4, CD004161	12
206	Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol. 2016 , 133, 63-75	16
205	Effectiveness of long-acting antipsychotics in clinical practice : 1. A retrospective, 18-month follow up and comparison between paliperidone palmitate, risperidone long-acting injection and zuclopenthixol decanoate. 2016 , 6, 22-32	12
204	Higher than recommended dosages of antipsychotics in male patients with schizophrenia are associated with increased depression but no major neurocognitive side effects: Results of a cross-sectional pilot naturalistic study. 2017 , 75, 113-119	2
203	Classics in Chemical Neuroscience: Haloperidol. 2017 , 8, 444-453	34
202	Chlorpromazine dose for people with schizophrenia. 2017 , 4, CD007778	11
201	Treatment of Bipolar Disorder in a Lifetime Perspective: Is Lithium Still the Best Choice?. 2017 , 37, 713-727	30
200	Investigational dopamine antagonists for the treatment of schizophrenia. 2017 , 26, 687-698	12
199	Risk excess of mortality and use of antipsychotics: a case-noncase study. 2017 , 32, 1-5	4
198	Frequency and correlates of anticholinergic use among patients with schizophrenia in Denmark: A Nation-wide pharmacoepidemiological study. 2017 , 255, 198-203	6

197	Brain volume changes over the first year of treatment in schizophrenia: relationships to antipsychotic treatment. 2017 , 47, 2187-2196	25
196	La recherche d'un dosage minimal d'antipsychotiques: construire une décision partagée avec les personnes souffrant de psychose. 2017 , 175, 617-623	1
195	Late Reduction of Cocaine Cravings in a Randomized, Double-Blind Trial of Aripiprazole vs Perphenazine in Schizophrenia and Comorbid Cocaine Dependence. 2017 , 37, 657-663	9
194	Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. 2017 , 4, 694-705	66
193	Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association. 2017 , 41, 211-216	14
192	From the closed ward to Soteria: a professional and personal journey. 2017 , 9, 369-375	2
191	Mapping the evidence on pharmacological interventions for non-affective psychosis in humanitarian non-specialised settings: a UNHCR clinical guidance. 2017 , 15, 197	2
190	A Study on Discontinuation Rate on Maintenance Treatment of Antipsychotic Agents in Schizophrenic Patients. 2017 , 20, 69	1
189	Psychotropic prescriptions for the treatment of schizophrenia in an outpatient clinic. 2017 , 39, 165-172	2
188	Public health psychopharmacology: a new research discipline comes of age?. 2018 , 27, 24-28	2
187	The use of chemogenetics in behavioural neuroscience: receptor variants, targeting approaches and caveats. 2018 , 175, 994-1003	50
186	Antipsychotics use: 2006-2013 trends in prevalence and incidence and characterization of users. 2018 , 74, 619-626	10
185	A quantitative analysis of antipsychotic prescribing trends for the treatment of schizophrenia in England and Wales. 2018 , 9, 2054270418758570	14
184	Negative symptoms of schizophrenia: new developments and unanswered research questions. 2018 , 5, 664-677	159
183	Prevalence and pattern of antipsychotic induced movement disorders in a tertiary care teaching hospital in India - a cross-sectional study. 2018 , 22, 101-108	4
182	A novel psychoanalytical approach: An electrochemical ligand-binding assay to screen antipsychotics. 2018 , 100, 139-147	4
181	The development of antipsychotic drugs. 2018 , 2, 2398212818817498	5
180	Assessing the robustness of direct meta-analysis in the presence of heterogeneity. 2018 , 7, 1009-1025	2

179	A thematic analysis assessing clinical decision-making in antipsychotic prescribing for schizophrenia. 2018 , 18, 290	2
178	Transcranial Direct Current Stimulation, Symptomatology, and Cognition in Psychosis: A Qualitative Review. 2018 , 12, 94	13
177	Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: A 1-year double-blind randomized clinical trial. 2018 , 28, 1024-1034	6
176	Hydrogen bond dynamics and conformational flexibility in antipsychotics. 2019 , 21, 15463-15470	1
175	Psychopharmacological Treatment of Schizophrenia Over Time in 30 908 Inpatients: Data From the AMSP Study. 2019 , 22, 560-573	17
174	Pattern of use of clozapine in Spain. Variability and under-prescription. 2019 , 12, 151-162	
173	Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8-week, double-blind, multicenter, randomized controlled study. 2019 , 39, 173-182	11
172	Study on risk factors of extrapyramidal symptoms induced by antipsychotics and its correlation with symptoms of schizophrenia. 2019 , 32, e100026	12
171	Clinical Characteristics, Drug Adherence to Antipsychotics and Medical Use Trends in Patients First Diagnosed with Psychotic Disorder: A Preliminary Study. 2019 , 22, 42	1
170	A quantum chemical approach representing a new perspective concerning agonist and antagonist drugs in the context of schizophrenia and Parkinson's disease. 2019 , 14, e0224691	9
169	The pharmacological management of acute behavioural disturbance: Data from a clinical audit conducted in UK mental health services. 2019 , 33, 472-481	6
168	Cross-species examination of single- and multi-strain probiotic treatment effects on neuropsychiatric outcomes. 2019 , 99, 160-197	11
167	Pattern of use of clozapine in Spain. Variability and under-prescription. 2019 , 12, 151-162	8
166	A Brief Guide to Medications for Psychosis. 2020 , 537-560	1
165	Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. 2020 , 177, 342-353	65
164	Genetic polymorphism in catechol-O-methyltransferase associated with the functional connectivity of frontostriatal circuits in first episode schizophrenia patients. 2020 , 51, 2134-2142	1
163	Synthesis and pharmacological evaluation of piperidine (piperazine)-amide substituted derivatives as multi-target antipsychotics. 2020 , 30, 127506	4
162	Trend survey on adverse event profiles of antipsychotic long-acting injections and oral agents using the Japanese adverse drug event report database. 2020 , 291, 113249	3

161	Prevalence of Extrapyrarnidal Symptoms in In-Patients With Severe Mental Illnesses: Focus on Parkinsonism. 2020 , 11, 593143	2
160	Magnitude, Nature, and Risk Factors of Adverse Drug Reactions Associated with First Generation Antipsychotics in Outpatients with Schizophrenia: A Cross-Sectional Study. 2020 , 9, 205-217	3
159	New information of dopaminergic agents based on quantum chemistry calculations. 2020 , 10, 21581	8
158	Prescription patterns of first- and second-generation antipsychotic drugs in the French population. 2020 , 34, 603-611	2
157	Proniosomes as a Carrier System for Transdermal Delivery of Clozapine. 2020 , 1-24	8
156	Towards personalized pharmacology: Antipsychotics and schizophrenia. 2021 , 76, 137-147	0
155	The chemical interaction between the neurotransmitter dopamine and the antipsychotic drugs olanzapine and quetiapine. 2021 , 881, 114946	3
154	The Basal Ganglia. 2021 , 141-165	
153	Side-effect monitoring of continuing LAI antipsychotic medication in UK adult mental health services. 2021 , 11, 2045125321991278	
152	Main interactions of dopamine and risperidone with the dopamine D2 receptor. 2021 , 23, 14224-14230	0
151	The roles of serotonin in cell adhesion and migration, and cytoskeletal remodeling. 2021 , 15, 261-271	0
150	Intramuscular midazolam, olanzapine, or haloperidol for the management of acute agitation: A multi-centre, double-blind, randomised clinical trial. 2021 , 32, 100751	5
149	Empagliflozin Effectively Attenuates Olanzapine-Induced Body Weight Gain in Female Wistar Rats. 2021 , 12, 578716	1
148	American psychiatry in the new millennium: a critical appraisal. 2021 , 1-9	12
147	Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia". 2021 , 41, 266-324	8
146	From the margins to the NICE guidelines: British clinical psychology and the development of cognitive behaviour therapy for psychosis, 1982â2002. 095269512110277	
145	Efficacy and safety of clozapine in psychotic disorders-a systematic quantitative meta-review. 2021 , 11, 487	7
144	Principles of Pharmacological Treatment in Schizophrenia. 515-524	1

143	Approaches to Treatment-Resistant Patients. 540-560	1
142	Neurological Complications of Antipsychotic Drugs. 561-576	5
141	Psychopharmaka. 2006 , 820-864	3
140	Dopamine Receptors and the Treatment of Schizophrenia. 2010 , 431-477	5
139	A new category of psychotropic drugs: neuroactive lipids as exemplified by ethyl eicosapentaenoate (E-E). 2002 , 59, 171-99	15
138	Psychopharmakotherapie âKlinisch-empirische Grundlagen. 2008 , 627-667	0
137	Psychopharmaka. 2007 , 819-868	4
136	Schizophrene Stfungen. 2008 , 847-872	1
135	Psychopharmaka. 2008 , 773-817	3
134	Psychopharmaka. 2008 , 775-819	1
133	Psychopharmaka. 2009 , 767-810	1
132	Psychopharmaka. 2010 , 797-842	3
131	Psychopharmaka. 2004 , 704-749	1
130	Psychopharmakotherapie in der Rehabilitation. 2004 , 129-133	3
129	Psychopharmaka. 2011 , 813-858	1
128	Psychopharmaka. 2012 , 833-879	1
127	Psychopharmaka. 2016 , 663-690	4
126	Psychopharmaka. 2018 , 733-761	3

125	Psychopharmaka. 2019 , 927-959		2
124	Antipsychotic drugs. 2007 , 545-556		2
123	Antipsychotic Drugs. 2009 , 487-492		1
122	PSYCHOSIS AND SCHIZOPHRENIA. 2009 , 797-815		1
121	Regulatory issues in Europe. 2001 , 21, 545-8		6
120	Naturalistic study of the antipsychotic medication review service at the Maudsley Hospital. 2002 , 26, 291-294		2
119	Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders. <i>Neuropsychiatric Disease and Treatment</i> , 2005 , 1, 89-108	3,1	8
118	Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. <i>Neuropsychiatric Disease and Treatment</i> , 2007 , 3, 13-39	3,1	24
117	The use of amisulpride in the treatment of acute psychosis. 2007 , 3, 3-11		13
116	Modulation of dopamine D2 receptors as a basis of antipsychotic effect. 2003 , 49-67		4
115	Comparative effectiveness of antipsychotic drugs in schizophrenia. 2000 , 2, 373-9		9
114	Treatment-refractory schizophrenia. 2004 , 6, 61-70		23
113	The German Research Network on Schizophrenia--impact on the management of schizophrenia. 2006 , 8, 115-21		13
112	Pharmacologic treatment of schizophrenia. 2010 , 12, 345-57		67
111	The impact of the National Institute for Health Research Health Technology Assessment programme, 2003-13: a multimethod evaluation. 2015 , 19, 1-291		16
110	Clinical Pharmacology and Medication-Associated Side Effects: A Review of Second-Generation Antipsychotics for Schizophrenia. 2007 , 1, 135-146		2
109	Drug Treatment of Depressive Symptoms in Schizophrenia. 2008 , 1, 328-340		10
108	Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters. 2013 , 6, 186-96		16

- 107 Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. **2011**, 72, 75-80 26
- 106 Pharmacologic treatment of first-episode schizophrenia: a review of the literature. **2012**, 14, 6
- 105 Assessment of the Latent Adverse Events of Antipsychotic Treatment Using a Subjective Questionnaire in Japanese Patients with Schizophrenia. **2017**, 15, 132-137 10
- 104 Low dose typical antipsychotics â brief evaluation. **2001**, 25, 276-276
- 103 Atypische Neuroleptika. **2001**, 23,
- 102 Conditions for detained patients. **2002**, 26, 36-36
- 101 Non-refractory schizophrenia. **2002**, 9-20
- 100 Psychiatric Emergencies. **2003**, 117-127
- 99 Uso de agentes antipsicticos en Espaa durante 1985-2000. **2003**, 10, 313-318
- 98 Tratamiento antipsictico en la esquizofrenia: las opciones atpicas y la gua NICE. **2003**, 10, 502-516
- 97 Psychopharmaka. **2004**, 769-810
- 96 Differentielle Anstze zur pharmakologischen Rezidivprophylaxe schizophrener Strungen. **2004**, 233-245
- 95 Molecular Medicine and the Prospects for Prevention and Early Intervention in Schizophrenia. **2004**, 355-366
- 94 Indikationsabhngige Durchfhrung und Bewertung der Elektrokonvulsionstherapie. **2004**, 343-461
- 93 Schizophrene Psychosen. **2004**, 109-160
- 92 Extrapiramidal-motorische Strungen (EPS): Ihre Bedeutung zu Zeiten der klassischen Neuroleptika im Vergleich zur modernen Antipsychotika-Therapie. **2004**, 19-60
- 91 Schizophrenia. **2005**, 7-106
- 90 Lo viejo frente a lo nuevo: sopesar los datos entre los antipsicticos de primera y segunda generacin. **2005**, 12, 223-230

- 89 Mecanismos de acción de los medicamentos antipsicóticos de segunda generación en la esquizofrenia: conocimientos obtenidos a partir de los estudios de imágenes cerebrales. **2005**, 12, 231-244
- 88 References. **2005**, 485-513
- 87 3 Biologische therapievormen. **2006**, 37-81
- 86 Neuroleptic drugs. **2006**, 2438-2489
- 85 Ziprasidone alone or in combination for acute mania.
- 84 Place des neuroleptiques atypiques dans la prise en charge du delirium et des nausées chez le patient palliatif. **2007**, 22, 95 1
- 83 Kapitel 8 Literaturverzeichnis. **2007**, 167-196
- 82 Activité anxiolytique de la cyamfazine : rôle des récepteurs sérotoninergiques. **2007**, 83, 595 0
- 81 Evidenzbasierung und leitliniengestützte Therapie in der Psychiatrie. **2008**, 971-983
- 80 Do Clinical Trials Always Benefit Patients?. **2008**, 13, 95-109
- 79 Antipsychotic Drugs. **2008**, 577-594 1
- 78 Pharmakotherapie der Schizophrenie (ICD-10 F2): Akut-, Notfall- und Langzeitbehandlung. **2009**, 55-94
- 77 Psychomotorische Erregungszustände. **2009**, 69-85
- 76 Therapieresistente Schizophrenie (ICD-10 F2). **2009**, 117-130
- 75 NEUROLEPTIC DRUGS. **2009**, 185-373
- 74 Comparative Efficacy and Safety of First - and Second-Generation Antipsychotics in the Treatment of Schizophrenia: Facts and Fiction. **2010**, 389-401
- 73 Disinhibition of Prefrontal Cortex Neurons in Schizophrenia. **2010**, 99-111
- 72 Maintenance pharmacotherapy in schizophrenia. *Medical Psychiatry*, **2009**, 174-184

- 71 An update of meta-analyses on second-generation antipsychotic drugs for schizophrenia. *Medical Psychiatry*, **2009**, 164-173 1
- 70 Schizophrenia. **2009**, 9-122
- 69 A survey of antipsychotic polypharmacy in outpatients at Nagoya University Hospital. *Clinical Neuropsychopharmacology and Therapeutics*, **2010**, 1, 43-49 0.2
- 68 Ziprasidone alone or in combination for acute mania.
- 67 Pharmacotherapie. **2011**, 199-203
- 66 Psychopharmakotherapie âKlinisch-empirische Grundlagen. **2011**, 731-766 2
- 65 Comparative Efficacy and Effectiveness in the Drug Treatment of Schizophrenia. 525-539
- 64 Experimental Epidemiology. 243-261
- 63 Neuroleptika. **2012**, 219-223
- 62 Author's reply. *British Journal of Psychiatry*, **2012**, 200, 257-257 5.4
- 61 Psychopharmaka. **2013**, 821-864
- 60 Antipsychotics for people with epilepsy and psychosis.
- 59 Psychopharmaka. **2014**, 921-965
- 58 Therapie Psychischer Erkrankungen - Pages 1-91. **2014**, 1-91
- 57 Antipsychotics for people with epilepsy and psychosis.
- 56 Therapie Psychischer Erkrankungen - Pages e1-e96. **2015**, e1-e96
- 55 Psychopharmaka. **2015**, 939-981 2
- 54 PsychiatryâNew Drugs. **2015**, 63-85

53 Zentrales Nervensystem. **2015**, 229-415

52 Pharmacotherapy. **2016**, 39-61

51 Quality of Life and Health Costs: The Feasibility of Cost-Utility Analysis in Schizophrenia. **2016**, 175-183

50 Ricerca e impiego degli psicofarmaci. *Rivista Sperimentale Di Freniatria*, **2016**, 23-42

o

49 Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 13. Auflage. **2017**, 1-111

48 Psychopharmaka. **2017**, 681-708

47 Neuroleptika in der Anästhesiologie. **2017**, 1-6

46 Zentrales Nervensystem. **2018**, 253-445

45 Neuroleptika in der Anästhesiologie. *Springer Reference Medizin*, **2019**, 275-280

o

44 Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 14. Auflage. **2019**, 1-119

43 Management of schizophrenia and bipolar disorder in pediatric practice. *Ukrains Kyi Visnyk Psykhonevrolohi*, **2019**, 27, 38-47

0.1

42 Antipsychotics: Clinical Effectiveness. *Current Clinical Psychiatry*, **2020**, 215-230

0.2

41 Tackling myths of common prescribing patterns in schizophrenia amongst Egyptian psychiatrists. *Middle East Current Psychiatry*, **2020**, 27,

2.4

o

40 Psychopharmaka. **2020**, 781-814

4

39 Aktuelle Aspekte der Langzeittherapie bei Schizophrenie. **2006**, 133-145

38 Pharmakotherapie neuropsychiatrischer Notfall- und Akutsituationen. **2006**, 1-102

37 Clinical Psychopharmacology and Other Somatic Therapies. **2008**, 577-634

36 Therapie mit Antipsychotika und Antidepressiva. **2007**, 89-102

35	Understanding antipsychotic "atypicality": a clinical and pharmacological moving target. <i>Journal of Psychiatry and Neuroscience</i> , 2003 , 28, 275-84	4.5	57
34	Using Atypical Antipsychotics in Primary Care. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2002 , 4, 233-241		
33	Atypical antipsychotics in the treatment of schizophrenia. Users' experiences of treatments must be considered. <i>BMJ: British Medical Journal</i> , 2001 , 322, 924-5; author reply 927-8		1
32	Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. <i>MedGenMed: Medscape General Medicine</i> , 2004 , 6, 5		13
31	Use of neuroleptics: study of institutionalized elderly people in Montreal, Que. <i>Canadian Family Physician</i> , 2005 , 51, 696-7	0.9	4
30	The future of pharmacotherapy for schizophrenia. <i>World Psychiatry</i> , 2003 , 2, 81-6	14.4	5
29	Effectiveness of antipsychotics: is the CATIE trial a tsunami?. <i>Canadian Family Physician</i> , 2007 , 53, 97-8	0.9	3
28	Response of pyromania to biological treatment in a homeless person. <i>Neuropsychiatric Disease and Treatment</i> , 2005 , 1, 277-80	3.1	2
27	Symptom control and patient adherence to treatment: key goals in the treatment of psychosis. <i>Psychiatry</i> , 2004 , 1, 18-9		
26	Lipid profile in antipsychotic drug users: A comparative study. <i>ARYA Atherosclerosis</i> , 2013 , 9, 198-202	0.7	4
25	Polypharmacy in the management of patients with schizophrenia on risperidone in a tertiary-care hospital in Malaysia. <i>Mental Health in Family Medicine</i> , 2013 , 10, 37-43		1
24	What does schizophrenia teach us about antipsychotics?. <i>Canadian Journal of Psychiatry</i> , 2015 , 60, S14-8	4.8	4
23	Psychopharmacological treatment for schizophrenia: less is more. <i>Shanghai Archives of Psychiatry</i> , 2015 , 27, 368-70		
22	From the Second Half of the Twentieth Century to the Early Twenty-First: The Psychopharmacologic Era. 2022 , 237-326		
21	Schizophrenia and Related Psychoses. 1-224		
20	Psychopharmaka. 2021 , 689-725		0
19	Analgesic Effects of Oxycodone in Combination With Risperidone or Ziprasidone: Results From a Pilot Randomized Controlled Trial in Healthy Volunteers.. <i>Frontiers in Pain Research</i> , 2022 , 3, 752256	1.4	
18	Drug-Induced Oxidative Stress and Cellular Toxicity. <i>Molecular and Integrative Toxicology</i> , 2021 , 73-113	0.5	

17 Zentrales Nervensystem. **2022**, 301-510

16 A Study on the Evaluation of Polyenoic Vegetable Oils and Their Female Health Benefits Based on Time Series Analysis Model: The Case of Peony Seed Oil.. *Journal of Healthcare Engineering*, **2022**, 2022, 3127698 3.7

15 The D2R-DISC1 protein complex and associated proteins are altered in schizophrenia and normalized with antipsychotic treatment.. *Journal of Psychiatry and Neuroscience*, **2022**, 47, E134-E147 4.5 ○

14 Histamine H1 Receptor in Basal Forebrain Cholinergic Circuit: A Novel Target for the Negative Symptoms of Schizophrenia?. *Neuroscience Bulletin*, **2021**, 38, 558 4.3 ○

13 Sex differences in antipsychotic-related triglyceride levels are associated with metabolic hormone differences in patients with severe mental disorders.. *Schizophrenia Research*, **2022**, 243, 55-63 3.6

12 New Paradigms of Old Psychedelics in Schizophrenia. *Pharmaceuticals*, **2022**, 15, 640 5.2 1

11 Second-Generation AntipsychoticsâEffectiveness and Tolerability: A Review of Real-World Studies in Patients with Schizophrenia and Related Disorders. **2022**, 11, 4530 2

10 Adherence to Antipsychotic Drugs by Medication Possession Ratio for Schizophrenia and Similar Psychotic Disorders in the Republic of Korea: A Retrospective Cohort Study. **2022**, 20, 491-497 1

9 Fixed Dose Combination Tablets of Aripiprazole and Divalproex Sodium: a Pilot Pharmacokinetic Study in Human Volunteers. **2022**, 23,

8 Evolution of antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia in the real-life: A 4-year follow-up naturalistic study. **2022**, 248, 279-286 ○

7 Optimizing subjective wellbeing with amisulpride in first episode schizophrenia or related disorders. 1-6 ○

6 Key concepts for informed health choices. 3.1: Evidence should be relevant. 014107682211407 ○

5 Intrinsic Therapeutic Link between Recuperative Cerebellar Con-Nectivity and Psychiatry Symptom in Schizophrenia Patients with Comorbidity of Metabolic Syndrome. **2023**, 13, 144 ○

4 Antipsychotic-based machine learning models may help prediction of tardive dyskinesia in patients with schizophrenia. **2023**, 252, 33-35 ○

3 Depression, Angststörungen, bipolare Störung, Schizophrenie, Aufmerksamkeitsdefizithyperaktivitätssyndrom. **2022**, 451-495 ○

2 Conditioned catalepsy vs. Increase in locomotor activity induced by haloperidol. **2023**, 802, 137174 ○

1 Dopamine delivery systems based on C60 and C24 with B and N as substituents. ○